VJHemOnc is committed to improving our service to you

COSTEM 2019 | AML: mutant IDH1 inhibitor HMS-101

VJHemOnc is committed to improving our service to you

Michael Heuser

Michael Heuser, MD, Hannover Medical School, Hannover, Germany, discusses the aims, methods and findings of his study of the in vivo efficacy of the mutant IDH1 inhibitor HMS-101 and the structural resolution of a distinct binding site. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter